Literature DB >> 7815548

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.

A Steinkasserer1, R Harrison, A Billich, F Hammerschmid, G Werner, B Wolff, P Peichl, G Palfi, W Schnitzel, E Mlynar.   

Abstract

SDZ NIM 811 is a cyclosporin A analog that is completely devoid of immunosuppressive capacity but exhibits potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity. The mechanism of action of SDZ NIM 811 is clearly different from those of all other anti-HIV agents described so far. In cell-free assays, it is not an inhibitor of reverse transcriptase, protease, integrase, and it does not interfere with Rev or Tat function. SDZ NIM 811 does not down-regulate CD4 or inhibit fusion between infected and uninfected, CD4-expressing cells. p24 production from chronically HIV-infected cells is not impaired either. To elucidate the mode of action of SDZ NIM 811, we performed DNA PCR analysis in HIV-1 IIIB-infected MT4 cells in one cycle of virus replication. The effects of SDZ NIM 811 on the kinetics of viral DNA synthesis, appearance of two-long terminal repeat circles (2-LTR circles), and integration of DNA were studied. SDZ NIM 811 inhibited 2-LTR circle formation in a concentration-dependent manner, which is indicative of nuclear localization of preintegration complexes. Half-maximal inhibition was achieved at 0.17 microgram/ml; this concentration is close to the 50% inhibitory concentrations (0.01 to 0.2 microgram/ml) for viral growth inhibition. As expected, integration of proviral DNA into cellular DNA was also inhibited by SDZ NIM 811. Analysis of the viral particles produced by SDZ NIM 811-treated, chronically infected cells revealed amounts of capsid proteins, reverse transcriptase activity, and viral RNA comparable to those of the untreated control. However, these particles showed a dose-dependent reduction in infectivity (50% inhibitory concentration of 0.028 microgram/ml) which indicates that the assembly process is also impaired by SDZ NIM 811. Gag proteins are postulated to play a role not only in assembly but also in early steps of viral replication, e.g., nuclear localization of the preintegration complex. Recently, it was reported that HIV-1 Gag protein binds to cyclophilin A, the intracellular receptor for cyclosporin A. Interference with Gag-cyclophilin interaction may be the molecular basis for the antiviral activity of cyclosporin A and its analogs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815548      PMCID: PMC188647     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  [Functional inhibition by cyclosporin A of the lymphocyte receptor for the AIDS virus (HIV)].

Authors:  D Klatzmann; J P Laporte; A Achour; E Brisson; J Gruest; L Montagnier; J C Gluckman
Journal:  C R Acad Sci III       Date:  1986

2.  The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.

Authors:  M A Wainberg; A Dascal; N Blain; L Fitz-Gibbon; F Boulerice; K Numazaki; M Tremblay
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

3.  Correct integration of retroviral DNA in vitro.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

4.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

5.  Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

Authors:  S Sawada; G Suzuki; Y Kawase; F Takaku
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

6.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

Authors:  T M Folks; J Justement; A Kinter; C A Dinarello; A S Fauci
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

7.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

8.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

Review 9.  Immunologic abnormalities in the acquired immunodeficiency syndrome.

Authors:  H C Lane; A S Fauci
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

10.  Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.

Authors:  M Krönke; W J Leonard; J M Depper; S K Arya; F Wong-Staal; R C Gallo; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more
  30 in total

1.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Nef enhances HIV-1 infectivity via association with the virus assembly complex.

Authors:  Mingli Qi; Christopher Aiken
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

5.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

7.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

8.  Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.

Authors:  C Aberham; S Weber; W Phares
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.

Authors:  C Aiken
Journal:  Virology       Date:  1998-08-15       Impact factor: 3.616

10.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.